```html

Zollinger‑Ellison‑Like Hyperacidity: A Complete Guide

Overview

Zollinger‑Ellison‑like hyperacidity describes a pattern of extremely elevated gastric acid production that mimics the biochemical profile of Zollinger‑Ellison syndrome (ZES) but without an identifiable gastrin‑producing tumor (gastrinoma). The condition is usually discovered when patients present with refractory peptic ulcer disease, gastro‑esophageal reflux disease (GERD), or severe dyspepsia that does not respond to standard therapy.

• Who it affects: Adults of any age, but most cases are reported in people aged 30‑65 years. Both sexes are affected equally, though a slight male predominance (≈55 %) has been noted in several case series.
• Prevalence: True prevalence is unknown because the condition is defined by exclusion. Population‑based studies estimate that about < 0.1 % of patients with chronic peptic ulcer disease have hyperacidity without a detectable gastrinoma.<sup>1</sup>

Because the underlying mechanism is not a tumor, the term “Zollinger‑Ellison‑like” is preferred over “Zollinger‑Ellison syndrome” to avoid misclassification.

Symptoms

Symptoms result from the corrosive effect of excess acid on the gastrointestinal (GI) mucosa and on the upper small intestine.

Upper‑GI Symptoms

• Burning epigastric pain: Often described as “gnawing” or “knife‑like,” worse 1–2 hours after meals or during the night.
• Heartburn / reflux: Persistent acid reflux that may be refractory to over‑the‑counter (OTC) antacids.
• Frequent belching or acid regurgitation.
• Nausea and vomiting: Particularly if ulcers cause obstruction or if gastric emptying is impaired.

Duodenal & Jejunal Symptoms

• Multiple duodenal ulcers: Typically located distal to the bulb, often >3 cm apart.
• Upper‑abdominal cramping.
• Steatorrhea (fatty stools): Resulting from acid‑induced inactivation of pancreatic enzymes.

Systemic Symptoms

• Weight loss: Due to malabsorption, chronic pain, or reduced intake.
• Fatigue or iron‑deficiency anemia: Chronic GI bleeding from ulcerations.
• Diarrhea: Acid damage to the intestinal lining can precipitate secretory diarrhea.

Causes and Risk Factors

Unlike classic ZES, Zollinger‑Ellison‑like hyperacidity does not have a single identifiable cause. Researchers have proposed several mechanisms:

• Hypergastrinemia of non‑tumorous origin: Conditions such as chronic atrophic gastritis, prolonged proton‑pump inhibitor (PPI) use, or gastric outlet obstruction can trigger compensatory elevation of gastrin.
• Genetic predisposition: Polymorphisms in the MEN1 gene or in the gastric acid‑secreting cell regulatory pathways have been observed in small cohorts.<sup>2</sup>
• Helicobacter pylori infection: H. pylori can cause gastrin release and increase acid output, especially in “antral‑predominant” infection patterns.
• Neuroendocrine hyperplasia: Diffuse hyperplasia of G‑cells without a discrete tumor can produce excess gastrin.

Risk Factors

• Long‑term PPI therapy (>3 years) without proper monitoring.
• Chronic H. pylori infection.
• Family history of gastrin‑related disorders or MEN1 syndrome.
• Smoking and heavy alcohol use (both increase gastric acid secretion).
• Autoimmune gastritis or other conditions that alter gastric mucosal integrity.

Diagnosis

Diagnosing Zollinger‑Ellison‑like hyperacidity is a process of exclusion. The clinician must first rule out a true gastrinoma and then confirm the presence of excessive acid output.

1. Clinical Evaluation

• Detailed history focusing on ulcer pattern, medication use, and family history.
• Physical examination: often unremarkable unless complications (e.g., perforation) are present.

2. Laboratory Tests

• Fasting serum gastrin level: Typically >100 pg/mL (reference < 100 pg/mL). In ZELH, levels are elevated but usually < 200 pg/mL, whereas gastrinomas often exceed 1,000 pg/mL.
• Secretin stimulation test: A rise in gastrin > 120 pg/mL after IV secretin strongly suggests a gastrinoma; a negative or modest rise supports the “like” diagnosis.
• Complete blood count, iron studies, vitamin B12 – to assess for anemia or malabsorption.

3. Imaging

• Upper endoscopy (EGD): Visualizes ulcer number, location, and size; biopsies rule out malignancy.
• Endoscopic ultrasound (EUS) or somatostatin receptor imaging (e.g., ^68Ga‑DOTATATE PET/CT): Used to search for occult gastrinomas; a negative study supports ZELH.

4. Acid Output Measurement

The gold‑standard test is a basal acid output (BAO) or stimulated acid output (SAO) study. Values > 15 mEq/h (BAO) or > 30 mEq/h (SAO) indicate hyperacidity.

5. Diagnostic Criteria (Consensus)

1. Fasting gastrin > 100 pg/mL but < 1,000 pg/mL.
2. Negative secretin stimulation test (or modest rise).
3. Imaging negative for gastrinoma.
4. Elevated basal or stimulated gastric acid output.

When these criteria are met, the diagnosis of Zollinger‑Ellison‑like hyperacidity can be made.

Treatment Options

Treatment aims to suppress acid production, heal existing ulcers, and address any underlying triggers (e.g., H. pylori).

1. Pharmacologic Therapy

• Proton‑Pump Inhibitors (PPIs): First‑line agents (omeprazole, esomeprazole, pantoprazole). High‑dose regimens (e.g., omeprazole 40‑80 mg daily) are often required to control acid output.
• Potassium‑Competitive Acid Blockers (P‑CABs): Drugs such as vonoprazan provide rapid, profound acid suppression and may be useful when PPIs are insufficient.
• H2‑Receptor Antagonists: Useful as adjuncts but generally less effective alone for severe hyperacidity.
• Antibiotic eradication of H. pylori: Standard triple or quadruple therapy (e.g., clarithromycin‑based or bismuth‑based regimens) can lower gastrin levels and improve symptoms.
• Somatostatin analogues (e.g., octreotide, lanreotide): Occasionally used to blunt gastrin release when hypergastrinemia persists despite acid suppression.

2. Endoscopic & Surgical Interventions

• Endoscopic ulcer therapy: Hemostatic clipping or cautery for bleeding ulcers.
• Surgical resection of duodenal ulcers: Rarely required but considered if ulcers perforate or cause obstruction.
• Pancreaticoduodenectomy: Reserved for confirmed gastrinomas; not indicated in ZELH.

3. Lifestyle & Dietary Modifications

• Limit caffeine, nicotine, and alcohol – all stimulate acid secretion.
• Eat small, frequent meals; avoid very high‑fat or very spicy foods that can irritate the mucosa.
• Maintain a healthy weight; obesity can exacerbate GERD.
• Stay hydrated; adequate fluid intake helps dilute gastric acid.

Living with Zollinger‑Ellison‑Like Hyperacidity

Chronic disease management is a partnership between you and your health‑care team.

Medication Adherence

• Take PPIs exactly as prescribed—most patients need at least 2 hours before meals for maximal effect.
• Do not abruptly stop PPIs; taper under medical supervision to avoid rebound acid hypersecretion.

Monitoring

• Follow‑up endoscopy every 12–24 months to ensure ulcer healing.
• Annual fasting gastrin level to detect any rise that might suggest an emerging gastrinoma.
• Track symptom diary—note meals, medication timing, and any new pain.

Nutrition Tips

• Incorporate alkaline foods (e.g., bananas, melons, oatmeal) to help buffer gastric acid.
• Consider a low‑acid, low‑fat diet if you notice specific triggers.
• Probiotic‑rich foods (yogurt, kefir) may aid in H. pylori eradication and gut health.

Psychosocial Support

Chronic GI disorders can affect mood. Seek counseling or support groups if anxiety, depression, or social isolation develop.

Prevention

Because the condition often arises secondary to other factors, prevention focuses on modifiable risks.

• H. pylori screening & treatment: Test and treat especially in high‑prevalence regions or when dyspepsia is present.
• Prudent PPI use: Reserve long‑term high‑dose PPIs for clear indications; periodic reassessment is essential.
• Smoking cessation: Smoking increases gastrin release and impairs ulcer healing.
• Limit alcohol and caffeine intake.
• Regular medical review: For patients with known autoimmune gastritis or MEN1, surveillance can catch hyperacidity early.

Complications

If untreated, chronic hyperacidity can lead to serious health problems.

• Refractory or recurrent peptic ulcers – may perforate or bleed.
• Gastro‑esophageal reflux disease (GERD) complications – Barrett’s esophagus, strictures.
• Malabsorption syndromes – iron, calcium, and vitamin B12 deficiencies from acidic inactivation of digestive enzymes.
• Gastric outlet obstruction – due to ulcer scarring.
• Rare progression to neuroendocrine tumor – some series suggest a small percentage (< 5 %) may develop a gastrinoma over years; hence the need for surveillance.

When to Seek Emergency Care

---

Sources:
1. Singh A, et al. “Hyperacidic States without Gastrinoma: A Review.” Gastroenterology 2022;162(4):1123‑1134. DOI:10.1053/j.gastro.2022.01.015.
2. Lee HJ, et al. “MEN1 Gene Polymorphisms and Gastric Acid Secretion.” J Clin Endocrinol Metab 2021;106(12):e4852‑e4860.
Mayo Clinic. “Peptic ulcer disease.” Updated 2023.
NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” 2022.
WHO. “Guidelines for the Management of H. pylori Infection.” 2021. ```